Servier is the leading French independent pharmaceutical company worldwide with products achieving a combined annual turnover of €4.0 billion. We are very much a research-based company and we invest 25% of our consolidated turnover each year into R&D.

The following are the key areas for Servier R&D:
* Cardiovascular diseases 
* Diabetes 
* Neuroscience 
* Rheumatology
* Oncology

Servier Taiwan was established in 1986, the professional team is dedicated to improve the quality of healthcare in Taiwan.

Major products in Taiwan (launched or to be launched soon):
- Acertil (perindopril 4, 5mg), Acertil Plus, Preterax, Coveram, Viacoram
- Natrilix SR (indapamide 1.5mg) 
- Coralan (ivabradine) 
- Diamicron MR (gliclazide 30mg, 60mg) 
- Protos (strontium ranelate 2g) 
- Valdoxan (agomelatine 25mg)